Neuphoria Therapeutics (NEUP) Other Non-Current Assets (2021 - 2025)
Neuphoria Therapeutics (NEUP) posted quarterly Other Non-Current Assets of $79647.0 for Q4 2025, up 7.66% year-over-year from $73982.0 in Q4 2024, and up 1.38% quarter-over-quarter from $78564.0 in Q3 2025.
Neuphoria Therapeutics (NEUP) Other Non-Current Assets (2021 - 2025) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Other Non-Current Assets for 5 consecutive years, with $79647.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Assets rose 7.66% year-over-year to $79647.0; the TTM figure through Dec 2025 stood at $79647.0 (up 7.66% YoY), while the FY2025 annual figure was $77945.0, down 1.12% from the prior year.
- Other Non-Current Assets climbed to $79647.0 in Q4 2025 per NEUP's latest filing, from $78564.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $91636.6 in Q2 2021 and bottomed at $73982.0 in Q4 2024.
- Historically, Other Non-Current Assets has averaged $80143.4 across 5 years, with a median of $79180.4 in 2023.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets declined 9.11% — and 2025, when it climbed 7.66%.
- Neuphoria Therapeutics' Other Non-Current Assets stood at $91636.6 in 2021, then decreased by 6.98% to $85235.9 in 2022, then declined by 4.51% to $81396.0 in 2023, then slipped by 9.11% to $73982.0 in 2024, then rose by 7.66% to $79647.0 in 2025.
- Business Quant data shows NEUP's Other Non-Current Assets at $79647.0 in Q4 2025, $78564.0 in Q3 2025, and $77945.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.93 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.59 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.86 Bn | 53.73 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.42 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.19 Bn | 9.80 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 62.96 Mn |
| 10 | Neuphoria Therapeutics | 21.37 Mn | 1.93 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 79,647.00 |
| Sep 30, 2025 | 78,564.00 |
| Jun 30, 2025 | 77,945.00 |
| Mar 31, 2025 | 74,732.00 |
| Dec 31, 2024 | 73,982.00 |
| Sep 30, 2024 | 82,491.00 |
| Jun 30, 2024 | 78,826.00 |
| Mar 31, 2024 | 77,731.00 |
| Dec 31, 2023 | 81,396.00 |
| Jun 30, 2023 | 79,534.89 |
| Jun 30, 2022 | 85,235.93 |
| Jun 30, 2021 | 91,636.56 |